DAFNA Capital Management LLC Has $8.23 Million Stake in Biohaven Ltd. (NYSE:BHVN)

DAFNA Capital Management LLC increased its stake in Biohaven Ltd. (NYSE:BHVN - Free Report) by 17.7% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 220,235 shares of the company's stock after acquiring an additional 33,105 shares during the quarter. Biohaven makes up 2.1% of DAFNA Capital Management LLC's holdings, making the stock its 15th largest holding. DAFNA Capital Management LLC owned about 0.22% of Biohaven worth $8,226,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. Cubist Systematic Strategies LLC bought a new position in shares of Biohaven during the 4th quarter valued at $884,000. Boone Capital Management LLC acquired a new position in shares of Biohaven during the 4th quarter valued at about $13,499,000. Brown Advisory Inc. raised its stake in shares of Biohaven by 0.7% in the 4th quarter. Brown Advisory Inc. now owns 975,585 shares of the company's stock valued at $36,438,000 after acquiring an additional 7,226 shares in the last quarter. Bank of America Corp DE lifted its holdings in Biohaven by 40.5% in the 4th quarter. Bank of America Corp DE now owns 310,559 shares of the company's stock worth $11,599,000 after purchasing an additional 89,576 shares during the last quarter. Finally, BNP Paribas Financial Markets bought a new stake in Biohaven during the fourth quarter worth approximately $1,560,000. 88.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on BHVN. JPMorgan Chase & Co. reduced their price objective on shares of Biohaven from $72.00 to $68.00 and set an "overweight" rating for the company in a research note on Wednesday, March 5th. Robert W. Baird cut their target price on shares of Biohaven from $60.00 to $57.00 and set an "outperform" rating for the company in a research report on Monday, April 28th. HC Wainwright reaffirmed a "buy" rating and issued a $54.00 price target on shares of Biohaven in a research report on Tuesday, March 4th. Morgan Stanley cut their price objective on Biohaven from $69.00 to $63.00 and set an "overweight" rating for the company in a research report on Friday, March 7th. Finally, Deutsche Bank Aktiengesellschaft set a $60.00 target price on Biohaven and gave the company a "buy" rating in a research note on Thursday, March 20th. Fourteen research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $62.54.

Biohaven Trading Down 0.2 %

Shares of BHVN traded down $0.05 during mid-day trading on Friday, hitting $20.20. 1,105,302 shares of the company traded hands, compared to its average volume of 1,170,277. The business has a 50-day moving average of $23.44 and a 200 day moving average of $35.36. Biohaven Ltd. has a one year low of $15.79 and a one year high of $55.70. The stock has a market capitalization of $2.06 billion, a price-to-earnings ratio of -2.16 and a beta of 1.18.

Biohaven (NYSE:BHVN - Get Free Report) last released its earnings results on Monday, March 3rd. The company reported ($1.85) earnings per share for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.29). As a group, analysts anticipate that Biohaven Ltd. will post -8.9 earnings per share for the current year.

Insider Activity

In related news, Director John W. Childs acquired 32,700 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The stock was acquired at an average price of $30.47 per share, for a total transaction of $996,369.00. Following the completion of the acquisition, the director now owns 2,320,571 shares of the company's stock, valued at $70,707,798.37. This trade represents a 1.43 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 16.00% of the company's stock.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.